Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06585605 · ClinicalTrials.gov registry record

A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes

A clinical trial of Epilepsy and Movement Disorders, sponsored by Boston Children's Hospital.

Recruiting
Registry status
500
Enrollment target
1
Study location

NCT06585605: Recruiting study of Epilepsy and Movement Disorders, sponsored by Boston Children's Hospital.

NCT06585605 is a study of Epilepsy and Movement Disorders that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 500 participants, below the 949-participant average among 160 other Epilepsy trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06585605, a study of Epilepsy and Movement Disorders, is actively recruiting participants, sponsored by Boston Children's Hospital.

RECRUITING
Registry status
500 participants
Enrollment target
1
Study location

Study Summary

The Epilepsy-Dyskinesia Study aims to advance the understanding of the clinical and molecular spectrum of epilepsy-dyskinesia syndromes, monogenic diseases that cause both movement disorders and epilepsy. Addressing challenges in rare disease research -such as small, geographically dispersed patient populations and a lack of standardized protocols- the study employs a multinational retrospective survey endorsed by the International Parkinson and Movement Disorder Society. This survey seeks to collect comprehensive data on clinical features, disease progression, age of onset, genetic variants, and concurrent neurological conditions, standardizing data collection across countries to provide a unified understanding of these conditions. Through retrospective review and molecular data analysis, the study aims to identify patterns and correlations between movement and seizure disorders, uncovering genotype-phenotype relationships. The initiative\'s goals are to enhance understanding of epilepsy-dyskinesia syndromes, inform precision medicine approaches, and foster international collaboration.

Primary Outcome

The primary endpoint of this multi-center study will be the creation of the Epilepsy-Dyskinesia Study and the enrollment of 350 individuals in a shared database.

Study Locations (1)

Massachusetts

  • Boston Children's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2024-07-01
Est. Completion 2029-12-31
Boston Children's Hospital

462 total trials

What NCT06585605 shows while recruiting

NCT06585605 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 949-participant average among 160 other Epilepsy trials with a reported enrollment target (47% lower).

The record links to 10 conditions, with Epilepsy appearing as the primary indexed condition, and to 0 interventions.

NCT06585605 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06585605 about?

NCT06585605 is a clinical study titled "A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes". The Epilepsy-Dyskinesia Study aims to advance the understanding of the clinical and molecular spectrum of epilepsy-dyskinesia syndromes, monogenic diseases that cause both movement disorders and epilepsy. Addressing challenges in rare disease research -such as small, geographically dispersed patient...

What is the current status of trial NCT06585605?

This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2024-07-01. Estimated completion is 2029-12-31.

What conditions does trial NCT06585605 study?

This clinical trial studies the following conditions: Epilepsy, Movement Disorders, Neurologic Disorder, Epilepsy in Children, Dyskinesias.

Who is sponsoring clinical trial NCT06585605?

This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06585605 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Epilepsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06585605's enrollment target sits among peer trials

500 13th of 160 higher than 147 of 160 other Epilepsy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06585605, the US trial registry maintained by the National Library of Medicine. NCT06585605 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.